Minerva Neurosciences, Inc. Cash and Restricted Cash
Minerva Neurosciences, Inc. (NERV) had Cash and Restricted Cash of $24.75 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-07
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $24.75M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $32.76M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $82.40M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $12.39M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $24.75M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $32.76M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $82.40M 10-K · filed 2026-03-11 |
| 2025-09-30 | $12.39M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $15.35M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $17.39M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $21.46M 10-K · filed 2026-03-11 |
| 2024-09-30 | $26.63M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $30.98M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $34.92M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $41.01M 10-K · filed 2025-02-25 |
| 2023-09-30 | $47.00M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $51.90M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $36.08M 10-Q · filed 2024-05-01 |
| 2022-12-31 | $36.19M 10-K · filed 2024-02-22 |
| 2022-09-30 | $40.32M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $49.85M 10-Q · filed 2023-08-01 |
| 2022-03-31 | $55.05M 10-Q · filed 2023-05-15 |
| 2021-12-31 | $60.86M 10-K · filed 2023-03-08 |
| 2021-09-30 | $65.69M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $74.31M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $80.24M 10-Q · filed 2022-05-04 |
| 2020-12-31 | $25.46M 10-K · filed 2022-03-01 |
| 2020-09-30 | $32.62M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $32.35M 10-Q · filed 2021-08-02 |
| 2020-03-31 | $30.14M 10-Q · filed 2021-05-12 |
| 2019-12-31 | $21.51M 10-K · filed 2021-03-08 |
| 2019-09-30 | $38.01M 10-Q · filed 2020-11-02 |
| 2019-06-30 | $27.94M 10-Q · filed 2020-08-03 |
| 2019-03-31 | $30.71M 10-Q · filed 2020-05-04 |
| 2018-12-31 | $50.33M 10-K · filed 2020-03-09 |
| 2018-09-30 | $87.40M 10-Q · filed 2019-11-04 |
| 2018-06-30 | $68.79M 10-Q · filed 2019-08-05 |
| 2018-03-31 | $45.23M 10-Q · filed 2019-05-06 |
| 2017-12-31 | $26.13M 10-K · filed 2019-03-12 |
| 2017-09-30 | $36.33M 10-Q · filed 2018-11-05 |
| 2017-06-30 | $50.27M 10-Q · filed 2018-08-02 |
| 2017-03-31 | $68.97M 10-Q · filed 2018-05-03 |
| 2016-12-31 | $83.06M 10-Q · filed 2018-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |